{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:04:41Z","timestamp":1781078681760,"version":"3.54.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a predominant chronic liver condition globally and is strongly associated with obesity, diabetes mellitus, and dyslipidemia. Essential phospholipids (EPL) are recommended as supportive treatment for managing liver conditions, including MASLD or metabolic dysfunction-associated steatohepatitis, cirrhosis, and viral hepatitis. While efficacy of EPL as an adjunctive therapy in MASLD treatment has been established earlier, certain aspects of its usage such as the impact of standard-of-care parameters, effect of EPL on quality of life (QoL) and change in symptoms evaluation in patients with MASLD remain unexplored. The proposed trial aims to assess the efficacy and safety of EPL and the subsequent QoL of patients with MASLD associated with type 2 diabetes mellitus (T2DM) and\/or hyperlipidemia and\/or obesity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a multicenter, multinational, double-blind, randomized, two-arm, placebo-controlled, parallel-group, phase IV clinical trial. The trial is being conducted in approximately 190 patients who are randomized on a 1:1 basis either to the EPL arm (Essentiale\u00ae 1800\u00a0mg\/day orally\u2009+\u2009standard of care) or placebo arm (placebo\u2009+\u2009standard of care). The primary outcome is to assess the efficacy of EPL on hepatic steatosis, as measured by transient elastography, from baseline to 6\u00a0months. The secondary outcomes include change in QoL parameters, as measured by the Chronic Liver Disease Questionnaire\u2013metabolic dysfunction-associated steatotic liver disease\/ metabolic dysfunction-associated steatohepatitis and change in symptom evaluation (using the Global Overall Symptom scale) from baseline to 6\u00a0months for symptoms, including asthenia, feeling depressed, abdominal pain\/discomfort, or fatigue.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The current protocol design will allow to comprehensively explore the efficacy of EPL added to the standard of care on hepatic steatosis and QoL and its safety in patients with MASLD associated with T2DM and\/or hyperlipidemia and\/or obesity by assessing various outcome measures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>European Union Clinical Trials Register, EudraCT, 2021\u2013006069-39. Registered on March 13, 2022.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-024-08208-4","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T02:01:36Z","timestamp":1718071296000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of essential phospholipids on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease associated with type 2 diabetes mellitus and\/or hyperlipidemia and\/or obesity: study protocol of a randomized, double-blind, phase IV clinical trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Norbert","family":"Stefan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Hartleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branko","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Varona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,11]]},"reference":[{"key":"8208_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851\u201361.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"8208_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u201347.","journal-title":"Hepatology"},{"issue":"10","key":"8208_CR3","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537\u201364.","journal-title":"Cell"},{"issue":"7","key":"8208_CR4","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908\u201322.","journal-title":"Nat Med"},{"issue":"10290","key":"8208_CR5","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW-S, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212\u201324.","journal-title":"Lancet"},{"issue":"4","key":"8208_CR6","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","volume":"10","author":"N Stefan","year":"2022","unstructured":"Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022;10(4):284\u201396.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"8208_CR7","doi-asserted-by":"publisher","first-page":"155642","DOI":"10.1016\/j.metabol.2023.155642","volume":"146","author":"P Golabi","year":"2023","unstructured":"Golabi P, Paik JM, Kumar A, Al Shabeeb R, Eberly KE, Cusi K, et al. Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States. Metabolism. 2023;146:155642.","journal-title":"Metabolism"},{"issue":"23","key":"8208_CR8","first-page":"00420","volume":"S0168\u20138278","author":"A Roca-Fernandez","year":"2023","unstructured":"Roca-Fernandez A, Banerjee R, Thomaides-Brears H, Telford A, Sanyal A, Neubauer S, et al. Liver disease is a significant risk factor for cardiovascular outcomes - a UK Biobank study. J Hepatol. 2023;S0168\u20138278(23):00420\u20138.","journal-title":"J Hepatol"},{"issue":"9","key":"8208_CR9","doi-asserted-by":"publisher","first-page":"100525","DOI":"10.1016\/j.jhepr.2022.100525","volume":"4","author":"Z Younossi","year":"2022","unstructured":"Younossi Z, Aggarwal P, Shrestha I, Fernandes J, Johansen P, Augusto M, et al. The burden of non-alcoholic steatohepatitis: a systematic review of health-related quality of life and patient-reported outcomes. JHEP Rep. 2022;4(9):100525.","journal-title":"JHEP Rep"},{"key":"8208_CR10","unstructured":"New MASLD Nomenclature. AASLD. Available at https:\/\/www.aasld.org\/new-masld-nomenclature (Accessed April 2024)."},{"issue":"8","key":"8208_CR11","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/liv.13391","volume":"37","author":"ZM Younossi","year":"2017","unstructured":"Younossi ZM, Stepanova M, Henry L, Racila A, Lam B, Pham HT, et al. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. Liver Int. 2017;37(8):1209\u201318.","journal-title":"Liver Int"},{"issue":"2","key":"8208_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","volume":"68","author":"A Lonardo","year":"2018","unstructured":"Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J Hepatol. 2018;68(2):335\u201352.","journal-title":"J Hepatol"},{"issue":"7","key":"8208_CR13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","volume":"6","author":"G Targher","year":"2021","unstructured":"Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6(7):578\u201388.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"8208_CR14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.cmet.2023.01.006","volume":"35","author":"N Stefan","year":"2023","unstructured":"Stefan N, Schick F, Birkenfeld AL, Haring H-U, White MF. The role of hepatokines in NAFLD. Cell Metab. 2023;35(2):236\u201352.","journal-title":"Cell Metab"},{"issue":"5","key":"8208_CR15","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(5):1264\u201381.e4.","journal-title":"Gastroenterology"},{"issue":"17","key":"8208_CR16","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.3748\/wjg.v29.i17.2534","volume":"29","author":"KY Zeng","year":"2023","unstructured":"Zeng KY, Bao W-Y-G, Wang Y-H, Liao M, Yang J, Huang J-Y, et al. Non-invasive evaluation of liver steatosis with imaging modalities: New techniques and applications. World J Gastroenterol. 2023;29(17):2534\u201350.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"8208_CR17","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas T, Petroff D, Sasso M, Fan J-G, Mi Y-Q, L\u00e9dinghen VD, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022\u201330.","journal-title":"J Hepatol"},{"key":"8208_CR18","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.14421.1","volume":"7","author":"S Albhaisi","year":"2018","unstructured":"Albhaisi S, Sanyal A. Recent advances in understanding and managing non-alcoholic fatty liver disease. F1000Res. 2018;7:F1000. https:\/\/doi.org\/10.12688\/f1000research.14421.1. Faculty Rev-720.","journal-title":"F1000Res"},{"issue":"30","key":"8208_CR19","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.3748\/wjg.v24.i30.3361","volume":"24","author":"S Leoni","year":"2018","unstructured":"Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol. 2018;24(30):3361\u201373.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"8208_CR20","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/hep.21763","volume":"46","author":"P Puri","year":"2007","unstructured":"Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007;46(4):1081\u201390.","journal-title":"Hepatology"},{"issue":"3","key":"8208_CR21","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jhep.2021.04.013","volume":"75","author":"GJ Ooi","year":"2021","unstructured":"Ooi GJ, Meikle PJ, Huynh K, Earnest A, Roberts SK, Kemp W, et al. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis. J Hepatol. 2021;75(3):524\u201335.","journal-title":"J Hepatol"},{"key":"8208_CR22","unstructured":"Essentiale\u00ae\u00a0SmPC, Sanofi, 2023."},{"key":"8208_CR23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40267-021-00838-x","volume":"37","author":"AI Dajani","year":"2021","unstructured":"Dajani AI, Abuhammour A. Agents for the treatment of fatty liver disease: focus on essential phospholipids. Drugs Ther Perspect. 2021;37:249\u201364.","journal-title":"Drugs Ther Perspect"},{"issue":"3","key":"8208_CR24","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S1734-1140(11)70576-X","volume":"63","author":"K Gundermann","year":"2011","unstructured":"Gundermann K, Kuenker A, Kuntz E, Dro\u017adzik M. Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol Rep. 2011;63(3):643\u201359.","journal-title":"Pharmacol Rep"},{"key":"8208_CR25","first-page":"105","volume":"9","author":"K-J Gundermann","year":"2016","unstructured":"Gundermann K-J, Gundermann S, Drozdzik M, Prasad VGM. Essential phospholipids in fatty liver: a scientific update. Clin Exp Gastroenterol. 2016;9:105\u201317.","journal-title":"Clin Exp Gastroenterol"},{"issue":"2","key":"8208_CR26","first-page":"18","volume":"77","author":"IAM Vakhrushev","year":"2005","unstructured":"Vakhrushev IAM, Suchkova EV. Use of essentiale and cholagogum in prevention of cholelithiasis in fat hepatosis with concomitant cholecystitis. Ter Arkh [Article in Russian]. 2005;77(2):18\u201321.","journal-title":"Ter Arkh [Article in Russian]"},{"issue":"4","key":"8208_CR27","first-page":"CD013301","volume":"2019","author":"DL Varganova","year":"2019","unstructured":"Varganova DL, Pavlov CS, Casazza G, Nikolova D, Gluud C. Essential phospholipids for people with non-alcoholic fatty liver disease. Cochrane Database Syst Rev. 2019;2019(4):CD013301.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"8208_CR28","doi-asserted-by":"publisher","first-page":"e000341","DOI":"10.1136\/bmjgast-2019-000341","volume":"7","author":"IV Maev","year":"2020","unstructured":"Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Vovk EI, Shirokova EN, et al. Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities (MANPOWER study). BMJ Open Gastroenterol. 2020;7(1):e000341.","journal-title":"BMJ Open Gastroenterol"},{"issue":"3\u20134","key":"8208_CR29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajg.2015.09.001","volume":"16","author":"AIM Dajani","year":"2015","unstructured":"Dajani AIM, Abu Hammour AM, Zakaria MA, Al Jaberi MR, Nounou MA, Semrin AIM. Essential phospholipids as a supportive adjunct in the management of patients with NAFLD. Arab J Gastroenterol. 2015;16(3\u20134):99\u2013104.","journal-title":"Arab J Gastroenterol"},{"issue":"1","key":"8208_CR30","doi-asserted-by":"publisher","first-page":"e000307","DOI":"10.1136\/bmjgast-2019-000307","volume":"6","author":"IV Maev","year":"2019","unstructured":"Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Shirokova E, Starostin KM. Real-world comorbidities and treatment patterns among patients with non-alcoholic fatty liver disease receiving phosphatidylcholine as adjunctive therapy in Russia. BMJ Open Gastroenterol. 2019;6(1):e000307.","journal-title":"BMJ Open Gastroenterol"},{"issue":"Suppl 1","key":"8208_CR31","doi-asserted-by":"publisher","first-page":"S549","DOI":"10.1016\/S0168-8278(13)61365-3","volume":"58","author":"E Sas","year":"2013","unstructured":"Sas E, Grinevich V, Efimov O, Shcherbina N. 1366 beneficial influence of polyunsaturated phosphatidylcholine enhances functional liver condition and liver structure in patients with nonalcoholic steatohepatitis. Results of prolonged randomized blinded prospective clinical study. J Hepatol. 2013;58(Suppl 1):S549.","journal-title":"J Hepatol"},{"issue":"2","key":"8208_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000443344","volume":"9","author":"European Association for the Study of Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)","year":"2016","unstructured":"European Association for the Study of Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obes Facts. 2016;9(2):65\u201390.","journal-title":"Obes Facts"},{"key":"8208_CR33","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin J, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"key":"8208_CR34","unstructured":"European Union Clinical Trials Register. Clinical Trials Register. Accessed 13 Sep 2023."},{"key":"8208_CR35","unstructured":"Rubin DB. Multiple imputation for nonresponse in surveys. New Jersey: John Wiley & Sons, Inc.; 2004."},{"issue":"1","key":"8208_CR36","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12876-017-0652-3","volume":"17","author":"Y Honda","year":"2017","unstructured":"Honda Y, Kessoku T, Sumida Y, Kobayashi T, Kato T, Ogawa Y, et al. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. BMC Gastroenterol. 2017;17(1):96.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"8208_CR37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3346\/jkms.2017.32.1.60","volume":"32","author":"YH Lee","year":"2017","unstructured":"Lee YH, Kim JH, Kim SR, Jin HY, Rhee E-J, Cho YM, et al. Lobeglitazone, a novel thiazolidinedione, improves non-alcoholic fatty liver disease in type 2 diabetes: its efficacy and predictive factors related to responsiveness. J Korean Med Sci. 2017;32(1):60\u20139.","journal-title":"J Korean Med Sci"},{"issue":"2","key":"8208_CR38","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.pharep.2018.10.013","volume":"71","author":"G Handzlik-Orlik","year":"2019","unstructured":"Handzlik-Orlik G, Holecki M, Kozaczka J, Kukla M, Wyskida K, Kedzierski L, et al. Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease. Pharmacol Rep. 2019;71(2):183\u20138.","journal-title":"Pharmacol Rep"},{"issue":"2","key":"8208_CR39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/dom.13520","volume":"21","author":"M Shimizu","year":"2019","unstructured":"Shimizu M, Suzuki K, Kato K, Jojima T, Iijima T, Murohisa T, et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019;21(2):285\u201392.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"8208_CR40","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.3390\/jcm9103213","volume":"9","author":"L Vedtofte","year":"2020","unstructured":"Vedtofte L, Bahne E, Foghsgaard S, Bagger JI, Andreasen C, Strandberg C, et al. One year\u2019s treatment with the glucagon-like peptide 1 receptor agonist liraglutide decreases hepatic fat content in women with nonalcoholic fatty liver disease and prior gestational diabetes mellitus in a randomized, placebo-controlled trial. J Clin Med. 2020;9(10):3213.","journal-title":"J Clin Med"},{"issue":"4","key":"8208_CR41","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.2307\/2532847","volume":"52","author":"R Little","year":"1996","unstructured":"Little R, Yau L. Intent-to-treat analysis for longitudinal studies with drop-outs. Biometrics. 1996;52(4):1324\u201333.","journal-title":"Biometrics"},{"key":"8208_CR42","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1177\/009286150904300407","volume":"43","author":"PA Flyer","year":"2009","unstructured":"Flyer PA. Discussion: \u201cIncomplete data in clinical studies: analysis, sensitivity, and sensitivity analysis\u201d by Geert Molenberghs. Drug Inf J. 2009;43:437\u20139.","journal-title":"Drug Inf J"},{"key":"8208_CR43","unstructured":"Ratitch B, O\u2019Kelly M. Implementation of pattern-mixture models using standard SAS\/STAT procedures. Proceedings of PharmaSUG 2011 - Paper SP04."},{"issue":"4","key":"8208_CR44","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","volume":"67","author":"M Romero-Gomez","year":"2017","unstructured":"Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829\u201346.","journal-title":"J Hepatol"},{"issue":"36","key":"8208_CR45","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.3748\/wjg.v23.i36.6549","volume":"23","author":"S Singh","year":"2017","unstructured":"Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: a review. World J Gastroenterol. 2017;23(36):6549\u201370.","journal-title":"World J Gastroenterol"},{"key":"8208_CR46","unstructured":"FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. Available at https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease (Accessed May 2024)."},{"issue":"6","key":"8208_CR47","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497\u2013509.","journal-title":"N Engl J Med"},{"issue":"3","key":"8208_CR48","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41575-023-00880-2","volume":"21","author":"N Stefan","year":"2024","unstructured":"Stefan N, Lonardo A, Targher G. Role of steatotic liver disease in prediction and prevention of cardiometabolic diseases. Nat Rev Gastroenterol Hepatol. 2024;21(3):136\u20137.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8208_CR49","first-page":"61","volume":"17","author":"Z Gonciarz","year":"1988","unstructured":"Gonciarz Z, Besser P, Lelek E, Gundermann KJ, Johannes KJ. Randomised placebo-controlled double blind trial on \u2018essential\u2019 phospholipids in the treatment of fatty liver associated with diabetes. Med Chir Digest. 1988;17:61\u20135.","journal-title":"Med Chir Digest"},{"issue":"1","key":"8208_CR50","doi-asserted-by":"publisher","first-page":"e000368","DOI":"10.1136\/bmjgast-2019-000368","volume":"7","author":"IV Maev","year":"2020","unstructured":"Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Shirokova EN, Vovk EI, et al. Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia. BMJ Open Gastroenterol. 2020;7(1):e000368.","journal-title":"BMJ Open Gastroenterol"},{"issue":"3","key":"8208_CR51","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s40801-021-00250-x","volume":"8","author":"VT Ivashkin","year":"2021","unstructured":"Ivashkin VT, Maevskaya MV, Shirokova EN, Maev IV, Samsonov AA, Sas EI, et al. Correlation of objective endpoints and subjective patient-reported outcomes in NAFLD treatment with essential phospholipids: real-world data based on pooled analysis of observational studies. Drugs Real World Outcomes. 2021;8(3):369\u201382.","journal-title":"Drugs Real World Outcomes"},{"issue":"3","key":"8208_CR52","doi-asserted-by":"publisher","first-page":"405","DOI":"10.5009\/gnl14202","volume":"9","author":"JK Kim","year":"2015","unstructured":"Kim JK, Lee KS, Choi JR, et al. Usefulness of the controlled attenuation parameter for detecting liver steatosis in health checkup examinees. Gut Liver. 2015;9(3):405\u201310.","journal-title":"Gut Liver"},{"issue":"1","key":"8208_CR53","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1590\/s0004-2803.201800000-07","volume":"55","author":"J Paul","year":"2018","unstructured":"Paul J, Venugopal RV, Peter L, Shetty KNK, Shetti MP. Measurement of controlled attenuation parameter: a surrogate marker of hepatic steatosis in patients of nonalcoholic fatty liver disease on lifestyle modification \u2013 a prospective follow-up study. Arq Gastroenterol. 2018;55(1):7\u201313.","journal-title":"Arq Gastroenterol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08208-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-024-08208-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08208-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T03:48:04Z","timestamp":1718077684000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-024-08208-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,11]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["8208"],"URL":"https:\/\/doi.org\/10.1186\/s13063-024-08208-4","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,11]]},"assertion":[{"value":"15 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee at the Medical Faculty of the Eberhard Karls University and at the University Hospital T\u00fcbingen, Germany (Project Number: 251\/2022AMG1). The trial is being performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki, ICH GCP, and all applicable regulations. Written consent is obtained from each participant prior to the collection of data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NS has received speaking honoraria from Sanofi. MH has received lecture honoraria from Sanofi. BP and RV are employees of Sanofi and may hold shares or stock options in the company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"374"}}